Compare ANNX & RSKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | RSKD |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 859.6M |
| IPO Year | 2020 | 2021 |
| Metric | ANNX | RSKD |
|---|---|---|
| Price | $3.75 | $9.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $15.43 | $7.65 |
| AVG Volume (30 Days) | ★ 3.4M | 2.5M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.01 |
| Revenue Next Year | N/A | $11.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $3.70 |
| 52 Week High | $7.18 | $9.09 |
| Indicator | ANNX | RSKD |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 71.49 |
| Support Level | $3.71 | $4.33 |
| Resistance Level | $4.37 | N/A |
| Average True Range (ATR) | 0.24 | 0.47 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 43.65 | 97.78 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Riskified Ltd offers an AI-powered e-commerce risk intelligence platform that identifies the individual behind each online interaction for legitimacy, helping merchants (its customers) eliminate risk and uncertainty from their business. The company's core product, the Chargeback Guarantee, automatically approves or declines online orders with performance levels that vary in accordance with its merchants' priorities. Additionally, it offers other products that mitigate similar e-commerce risks for those same merchants, including Policy Protect, Dispute Resolve, and Account Secure. Geographically, Riskified generates maximum revenue from the United States, and the rest from other regions of the Americas, Europe, the Middle East and Africa (EMEA), and the Asia-Pacific (APAC) region.